WallStreetZenWallStreetZen

NASDAQ: BIOR
Biora Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for BIOR

Based on 1 analyst offering 12 month price targets for Biora Therapeutics Inc.
Min Forecast
$50.00+5,789.28%
Avg Forecast
$50.00+5,789.28%
Max Forecast
$50.00+5,789.28%

Should I buy or sell BIOR stock?

Based on 1 analyst offering ratings for Biora Therapeutics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BIOR stock forecasts and price targets.

BIOR stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-01-02

1 of 1

Forecast return on equity

Is BIOR forecast to generate an efficient return?
Insufficient data to display

Forecast return on assets

Is BIOR forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

BIOR revenue forecast

What is BIOR's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$3.5M+19,344.44%
Avg 2 year Forecast
$8.5M+47,122.22%
Avg 3 year Forecast
$9.1M+50,455.56%
BIOR's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BIOR revenue growth forecast

How is BIOR forecast to perform vs Biotechnology companies and vs the US market?
Company
717.48%
Industry
52.23%
Market
10%
BIOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIOR's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIOR vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BIOR$0.85$50.00+5,789.28%Buy
LPCN$3.81N/AN/A
AIM$0.42N/AN/A
MAIA$1.38N/AN/A
LABP$6.29N/AN/A

Biora Therapeutics Stock Forecast FAQ

Is Biora Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: BIOR) stock is to Buy BIOR stock.

Out of 1 analyst, 0 (0%) are recommending BIOR as a Strong Buy, 1 (100%) are recommending BIOR as a Buy, 0 (0%) are recommending BIOR as a Hold, 0 (0%) are recommending BIOR as a Sell, and 0 (0%) are recommending BIOR as a Strong Sell.

If you're new to stock investing, here's how to buy Biora Therapeutics stock.

What is BIOR's revenue growth forecast for 2024-2026?

(NASDAQ: BIOR) Biora Therapeutics's forecast annual revenue growth rate of 717.48% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 52.23%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10%.

Biora Therapeutics's revenue in 2024 is $18,000.On average, 1 Wall Street analysts forecast BIOR's revenue for 2024 to be $82,962,852, with the lowest BIOR revenue forecast at $82,962,852, and the highest BIOR revenue forecast at $82,962,852. On average, 1 Wall Street analysts forecast BIOR's revenue for 2025 to be $201,481,212, with the lowest BIOR revenue forecast at $201,481,212, and the highest BIOR revenue forecast at $201,481,212.

In 2026, BIOR is forecast to generate $215,703,415 in revenue, with the lowest revenue forecast at $215,703,415 and the highest revenue forecast at $215,703,415.

What is BIOR's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: BIOR) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is BIOR's Price Target?

According to 1 Wall Street analyst that have issued a 1 year BIOR price target, the average BIOR price target is $50.00, with the highest BIOR stock price forecast at $50.00 and the lowest BIOR stock price forecast at $50.00.

The Wall Street analyst predicted that Biora Therapeutics's share price could reach $50.00 by Jan 2, 2025. The average Biora Therapeutics stock price prediction forecasts a potential upside of 5,789.28% from the current BIOR share price of $0.85.

What is BIOR's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: BIOR) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.